glp-1 agonist prediabetes Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action The GLP-1 Agonists and Obesity:

Preclinical studies in animal models have demonstrated that GLP-1 receptor activation may reduce amyloid-beta accumulation, decrease tau phosphorylation, and protect neurons from oxidative damage

Velayati says the natural stability of these newer drugs allows them to survive stomach acid without a special chemical enhancer (like SNAC)

Less commonly, people taking GLP-1 medications can experience problems with the pancreas, stomach, intestines, gallbladder, or kidneys

doi: 10.1016/j.tem.2016.10.001 30 DuringMJCaoLZuzgaDSFrancisJSFitzsimonsHLJiaoXet al

This article dives deep into the benefits, risks, and safety strategies of GLP-1 and peptide therapies, while also highlighting how CoverWell offers unmatched protection for both patients and practices